DPH-362
Appearance
Clinical data | |
---|---|
Other names | PD129167 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C18H21N |
Molar mass | 251.373 g·mol−1 |
3D model (JSmol) | |
| |
|
DPH-362 is a simplified amitriptyline analog created by omission of the two-carbon dibenzosuberane bridge (the seven membered ring). The resulting compound still had activity in a test to explore TCA sodium channel blockers with analgesic properties.[1][2]
It is based on previous structures such as Spasmolytic A29 (one of the active ingredients in Ketogan)[3][4] and SKF-89976A.
Synthesis
[edit]γ-Butyrolactone is used in the synthesis of DPH-362.[5]
See also
[edit]References
[edit]- ^ Bölcskei H, Tarnawa I, Kocsis P (June 2008). "Voltage-gated sodium channel blockers, 2001-2006: An overview". Medicinal Chemistry Research. 17 (2–7): 356–368. doi:10.1007/s00044-007-9071-2.
- ^ Hudgens DP, Taylor C, Batts TW, Patel MK, Brown ML (December 2006). "Discovery of diphenyl amine based sodium channel blockers, effective against hNav1.2". Bioorganic & Medicinal Chemistry. 14 (24): 8366–8378. doi:10.1016/j.bmc.2006.09.010. PMC 2756728. PMID 17035036.
- ^ Petersen PV (1951). "Studies on a new spasmolytic compound 1,1-diphenyl-3-dimethylaminobutene-1 (A29), related to methadone, and on the combined use of this compound and a potent analgesic, ketobemidone (A21)". Acta Pharmacologica et Toxicologica. 7 (1): 51–64. doi:10.1111/j.1600-0773.1951.tb02849.x. PMID 14829296.
- ^ Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H (September 1998). "Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists". Biochemical Pharmacology. 56 (5): 553–559. doi:10.1016/s0006-2952(98)00088-4. PMID 9783723.
- ^ WO 2006023757, Brown ML, "Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents", published 2 March 2006, assigned to University of Virginia